1   Activation of the renin-angiotensin-aldosterone system is attenuated in hypertensive compared

2   to normotensive pregnancy

4   [1]Robin Shoemaker*, [2]Marko Poglitsch, [3]Hong Huang, [4]Katherine Vignes, [4]Aarthi Srinivasan,

5   [4]Cynthia Cockerham, [3]Aric Schadler, [3]John A. Bauer, [4]John M. O'Brien

[1] Department of Dietetics and Human Nutrition, University of Kentucky, Lexington KY, USA

[2] Attoquant Diagnostics GmbH, Vienna, Austria

[3]Department of Pediatrics, University of Kentucky, Lexington KY, USA

[4]Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of

Kentucky, Lexington KY, USA

Running Title: Attenuation of the RAAS in hypertensive versus normotensive pregnancy

*First and Corresponding Author:
Robin Shoemaker, PhD
Assistant Professor
University of Kentucky
Department of Dietetics and Human Nutrition
119 Funkhouser Building
Lexington, KY 40306
859-257-1031
Robin.shoemaker@uky.edu

Abstract

Hypertension during pregnancy increases the risk for adverse maternal and fetal outcomes, but mechanisms of pregnancy hypertension are not precisely understood. Elevated plasma renin activity and aldosterone concentrations play an important role in the normal physiologic adaptation to pregnancy. These effectors are reduced in patients with pregnancy hypertension, creating an opportunity to define features of the renin-angiotensin-aldosterone system (RAAS) that are characteristic of this disorder. In the current study, we used a novel LC-MS/MS-based methodology to develop comprehensive profiles of RAAS peptides and effectors over gestation in a cohort of n=74 pregnant women followed prospectively for the development of gestational hypertension and pre-eclampsia (HYP, n=27) versus remaining normotensive (NT, n=47). In NT pregnancy, the plasma renin activity surrogate, (PRA-S, calculated from the sum of [angiotensin I] + [angiotensin II) and aldosterone concentrations significantly increased from first to third trimester, accompanied by a modest increase in concentrations of angiotensin peptide metabolites. In contrast, in HYP pregnancies PRA-S and angiotensin peptides were largely unchanged over gestation, and third trimester aldosterone concentrations were significantly lower compared to NT pregnancies. Results indicate that the predominate features of pregnancies that develop HYP are stalled or waning activation of the RAAS in the second half of pregnancy (accompanied by unchanging levels of angiotensin peptides) and attenuated secretion of aldosterone.

Keywords: angiotensin, maternal, pregnancy hypertension, biomarkers, mass spectrometry, aldosterone

1. Introduction

New onset hypertension during pregnancy (gestational hypertension or pre-eclampsia) affects 5-10% of pregnancies, and the prevalence in the United States is rising[1]. Development of hypertension during pregnancy is associated with long-term health risks for both the mother and the offspring[2], and increases maternal risk for cardiovascular diseases later in life[3, 4]. Knowledge of mechanisms underlying perinatal hypertension could lead to improved strategies for the treatment and/or management of hypertension during pregnancy [5, 6].

The renin angiotensin aldosterone system (RAAS) is a master regulator of blood pressure and fluid homeostasis in pregnant and non-pregnant states[7, 8]. Activity of the RAAS is initiated by the enzymatic cleavage of a ten-amino acid peptide, angiotensin I (Ang I) from the N-terminus of angiotensinogen (AGT) by the enzyme renin in a highly regulated reaction. The rate of Ang I formation in plasma, also called plasma renin activity (PRA), is determined by the concentrations of active renin and AGT, where renin is rate-limiting. Ang I serves as a substrate for angiotensin-converting enzyme (ACE), resulting in the formation of angiotensin II (Ang II), the primary effector molecule of the RAAS. The concentration of active Ang II is controlled via negative feedback on renin [9], and by metabolism at the n- or c-terminal by amino- and carboxy peptidases in plasma, where the latter is considered to be a counter-regulatory arm of the RAAS. Cleavage of Ang II by angiotensin-converting enzyme 2 (ACE2) generates angiotensin-1-7(Ang 1-7)[10], a peptide with purported vasodilatory and other counter-effects to Ang II[11].

The classical effects of Ang II are mediated through the Ang II type 1 (AT_1) receptor, and include vasoconstriction, activation of the sympathetic nervous system, and stimulation of aldosterone release from the adrenal cortex[12, 13]. Outside of pregnancy, excess effects of Ang II and aldosterone are associated with inflammation, fibrosis, and endothelial dysfunction[14, 15], and abnormal function of the counter-regulatory arm of the RAAS has been described in many cardiovascular [16, 17], renal[18], and infectious disease states(i.e. COVID-19)[19].

In healthy pregnancy, there is pronounced activation of the RAAS, where PRA and

aldosterone concentrations are increased compared to non-pregnant states[20-22].

Upregulation of renin activity and aldosterone secretion play key roles in physiologic adaptations

to healthy pregnancy, such as promoting water and sodium reabsorption sufficient to support

the demand for a 40-50% expansion in blood volume[8, 23, 24]. In contrast, numerous studies

have demonstrated that pregnancies with pre-eclampsia or gestational hypertension have lower

plasma renin activity and lower aldosterone concentrations compared to normotensive

pregnancies. [21, 25-27]. Limited studies suggest the alternative RAAS may also play a role in

pregnancy, and that alterations in these components, e.g. Ang-1-7 and/or ACE2, are associated

with pre-eclampsia and small-for-gestational age infants[28-30]. The course of RAAS activity

over the course of gestation is not precisely understood in either normal or hypertensive

pregnancy[23, 31]. Understanding key deviations in the normal activity of the RAAS in

pregnancy could lead to improved detection or management of gestational hypertension and/or

pre-eclampsia.

RAS Fingerprint^{TM} is novel, liquid chromatography-tandem mass spectrometry (LC-

MS/MS)-based methodology for simultaneous quantification of multiple components of the

RAAS in a single sample. Outside of pregnancy, recent studies have utilized RAS Fingerprint^{TM}

(or RAS profiling) to generate a biochemical "snapshot" of RAAS activity reflective of disease

state in patients with hypertension[32], heart failure[33, 34], and other diseases[35, 36]. In the

current study, we used RAS Fingerprint to quantify key effectors (angiotensin peptides and

aldosterone) of the RAAS in a cohort of women followed prospectively for the development of

gestational hypertension and pre-eclampsia. Our objective was to define prominent features of

RAAS activity associated with the development of pregnancy hypertension.

2. Methods and Materials

Study Population

This is a secondary analysis of n=74 pregnant individuals enrolled in an ongoing study at the University of Kentucky. All subjects gave informed consent to participate in the study, which was approved by the University of Kentucky Institutional Review Board, and all study procedures/methods were performed in accordance with relevant guidelines and regulations. The cohort is comprised of pregnant individuals without pre-pregnancy hypertension, but otherwise meeting the following clinical risk factors for pre-eclampsia[37], where inclusion in the study were more than one of the following clinical risk factors: history of preterm preeclampsia, type 1 or 2 diabetes, renal or autoimmune disease; or more than two of the following clinical risk factors: nulliparity, obesity (BMI > 30), family history of pre-eclampsia, Black race, lower income, age 35 or older, previous pregnancy with small birth weight or adverse outcome, or in-vitro conception. Patients not meeting these criteria were recruited as controls. Exclusion criteria included age less than 18 or greater than 45 years, multifetal gestation, history of allergy to aspirin, gastrointestinal bleeding, severe peptic ulcer or liver dysfunction, patients on anticoagulant medications, and women with anomalous fetus.

Study Design and Groups

Pregnant women between 18 and 45 years of age in the first trimester of pregnancy were recruited at the time of their routine prenatal visits or ultrasound appointments in the first trimester screening and followed prospectively for the development of pre-eclampsia, gestational hypertension, and related pregnancy outcomes. Patients were treated according to standard clinical guidelines and data collected as part of routine clinical care. Demographic information was collected upon enrollment. Clinical data and maternal blood were collected at routine visits by trained study personnel at the first (11-16 weeks) and third (28-32 weeks) trimesters of pregnancy, and outcomes were recorded at delivery. Blood pressure was

measured following the American Heart Association Guidelines[38], and was determined as the

average of two consecutive measurements per arm assessed in a seated, resting position by

one observer. Clinical data and outcomes were obtained from electronic medical records

(EMR), and input into a REDcap database by study personnel. Maternal blood was collected

into red-top serum tubes and rested at room temperature for 60 minutes followed by

centrifugation, transfer into 200 uL single-use aliquots, and barcoding. Samples were stored at -

80°C until analysis.

Development of pre-eclampsia or gestational hypertension was the primary endpoint.

Pregnancy outcomes were determined after delivery by trained clinical staff. Pre-eclampsia was

diagnosed according to guidelines by the American College of Gynecologists[39]: either systolic

blood pressure (SBP) or diastolic blood pressure (DBP) greater than 140 or 90 mmHg,

respectively, measured at least four hours apart after 20 weeks gestation, and one of the

following: proteinuria of 300 mg in 24 hours or a urine to protein creatinine ratio = 0.3, elevated

serum creatine greater than 1.1 mg/dL, liver function tests (AST/ALT) double the upper limits of

normal, platelet counts of <100,00/microliter, flash pulmonary edema, or neurologic features

including blurry vision or headaches not relieved with medication. Gestational hypertension was

diagnosed as either SBP or DBP greater than 140 or 90 mmHg, respectively, after 20 weeks

gestation in women with previously normal blood pressure[39]. The following adverse outcomes

were also recorded: gestational diabetes, small for gestational age (defined as fetal weight

below the 10th percentile), postpartum hemorrhage, preterm premature rupture of membranes

(PPROM), pre-term labor or pre-term delivery (<34 weeks), presence of polyhydramnios, or fetal

death.

In the current study, patients were grouped for analysis based on whether they met the

primary endpoint of either pre-eclampsia or gestational hypertension (HYP, n=27), or remained

normotensive (NT, n=47). We then investigated differences in measured serum components of

the RAAS over gestation (in the first versus third trimester) and at each time point among NT

and HYP groups.

Quantification of angiotensin peptides, aldosterone, and equilibrium-based biomarkers PRA-S,

ACE-S, and the aldosterone to Ang II ratio (AA2-R) in serum using RAS Fingerprint^{TM}.

Serum concentrations of six angiotensin peptides (Ang I, Ang II, Ang III, Ang IV, Ang-1-5, and

Ang-1-7) and aldosterone were quantified by LC-MS/MS following a controlled ex vivo

equilibration (i.e. equilibrium analysis) that has been previously described[40-43]. Equilibrium

analysis generates a "snapshot" of RAAS activity in a sample that reflects the biochemical

features of the circulating RAAS, based on the principle that all components required to

generate angiotensin metabolites in vivo are present in plasma. Briefly, serum samples were

incubated at 37 °C for one hour to generate a controlled equilibrium, followed by stabilization

through addition of an enzyme inhibitor cocktail. Samples were spiked with stable isotope-

labeled internal standards at 200 pg/mL for each angiotensin metabolite. The samples were

subjected to C-18-based solid-phase-extraction, followed by LC-MS/MS analysis using a

reversed-phase analytical column (Acquity UPLC C18, Waters, Milford, Massachusetts, USA)

operating in line with a Xevo TQ-S triple quadruple mass spectrometer in multiple reaction

monitoring mode (Waters, Milford, Massachusetts, USA). Internal standards were used to

correct for peptide recovery of the sample preparation procedure for each analyte in each

individual sample. Analyte concentrations were determined using software

(MassLynx/Target/Lynx, Waters, Milford, Massachusetts, USA) via integration of the total ion

chromatogram obtained from a sum of quantifier transitions that have been optimized for

sensitivity and specificity, and integrated signals exceeded a signal-to noise ratio of 10. Analyte

concentrations were determined via linear calibration and reported in pmol/L. Batch

performance is evaluated based on calculated levels of calibrator and quality control samples

(must be within 15% of nominal concentration); lowest calibrator (lower limit of quantification –

LLOQ) must be within 20% of nominal concentration; at least 67% of all quality control and

calibrators must comply. The lower limits of quantification (LLOQs) for each peptide were:

angiotensin I: 5 pmol/L; angiotensin II: 4 pmol/L; angiotensin III: 4 pmol/L; angiotensin IV: 2

pmol/L; angiotensin-(1-5): 2 pmol/L; angiotensin-(1-7): 3 pmol/L, and aldosterone: 13 pmol/L.

For values below the LLOQ, means for each analyte and calculation of equilibrium-based

biomarkers were calculated using half the LLOQ[43].

Equilibrium concentrations of Ang I, Ang II, and aldosterone were used to calculate

biomarkers reflecting PRA, ACE activity, and the aldosterone to Ang II ratio (AA2-R), as

previously described[32, 41]. The plasma renin activity surrogate (PRA-S) was calculated from

the sum of the equilibrium concentrations of Ang I and Ang II ([eqAng I] + [eqAng I] (pmol/L); the

surrogate for ACE activity (ACE-S) was calculated from the ratio of the equilibrium

concentrations of Ang II to Ang I ([eqAng II] / [eqAng I] (pmol/L/pmol/L); the aldosterone to Ang

II ratio (AA2-R) was calculated by diving aldosterone concentrations by equilibrium

concentrations of Ang II ([Aldosterone] / [eqAng II] (pmol/L/pmol/L). PRA-S, ACE-S, and AA2-R

have been utilized as biomarkers of the RAAS that correlate with clinical parameters and/or

predict outcomes in numerous studies, including in humans with hypertension and/or primary

aldosteronism[32, 44-46], heart failure[33, 43, 47], COVID-19[48, 49], and others[50, 51].

Statistical Analysis

Statistical analyses were performed via GraphPad Prism version 9.5.1 (San Diego, CA, USA)

and SPSS Statistics version 24 (IBM, Armonk, NY). All data were assessed for normality, and

the appropriate parametric/nonparametric tests used. Clinical and demographic data were

analyzed for between-group differences (NT versus HYP), where continuous variables were

analyzed using paired t-tests, and categorical variables were analyzed using chi-square or

Fisher's exact test. For serum components of the RAAS, Mann-Whitney tests were applied for

between-groups analysis at each time point in independent samples, and within-group changes

from first to third trimester were determined using Wilcoxon matched-pairs signed rank tests. A

p-value less than 0.05 was considered statistically significant.

3. Results

Subject characteristics. Paired clinical data and biological samples from first and third trimester

visits were obtained for 74 women between April 2019 and May 2020. The cohort

demographics, clinical characteristics, and outcomes are described in Table 1. The cohort was

primarily Caucasian, with Black, Hispanic, and mixed-race individuals distributed fairly equally

among groups. The HYP group had a slightly greater risk profile compared to NT, with more

patients being primiparous, having a previous pre-eclamptic pregnancy, having type 1 diabetes,

and taking aspirin for the prevention of pre-eclampsia. The NT group contained slightly more

patients with type 2 diabetes, and with renal or autoimmune disease. First trimester BMI was

significantly greater in HYP compared to the NT, as was first and third trimester SBP and DBP,

although only four patients in the HYP received hypertension treatment. Duration of gestational

was significantly shorter in HYP versus NT groups.

The HYP group was comprised of twenty-three patients who developed gestational

hypertension and six patients that developed pre-eclampsia. Both NT and HYP patients

experienced adverse outcomes such as gestational diabetes, PPROM, polyhydramnios, and

postpartum hemorrhage. Slightly more HYP than NT patients developed gestational diabetes,

but no HYP patients had IUGR or pre-term labor/delivery, compared to two and three,

respectively, in the NT group.

Table 1. Patient demographics and clinical characteristics of women that developed gestational
hypertension or pre-eclampsia (HYP) in pregnancy or remained normotensive (NT).

Parameter	NT N=47	HYP N=27
Patient Demographics, n (%)		
Race		
Caucasian	33 (70)	20 (74)
Black or African American	7 (15)	4 (15)
Hispanic	6 (13)	2 (7)
Asian	1 (2)	0
Mixed race	0	1 (4)
Primiparous	19 (40)	14 (52)
Previous pre-eclampsia	6 (13)	8 (30)
Type 1 DM	7 (15)	9 (33)
Type 2 DM	5 (11)	2 (7)
Renal disease	1 (2)	0
Autoimmune disease	7 (15)	0
Medications		
Aspirin	22 (47)	18 (67)
Labetalol or Nifedipine	0	4 (15)
Clinical Characteristics, mean $\pm$ SD		
Age, years	30 ± 6	28 ± 6
BMI (1st trimester), kg/m^2	29 ± 7	$32 \pm 8^{\#}$
SBP, mmHg 1st Trimester 3rd Trimester	113 ± 11 115 ± 9	$122 \pm 9^{\#\#\#}$ $126 \pm 10^{\#\#\#\#}$
DBP, mmHg 1st Trimester 3rd Trimester	73 ± 8 73 ± 6	$80 \pm 6^{\#\#\#}$ $81 \pm 6^{\#\#\#\#}$
Gestational age at delivery, weeks	38.6 ± 1.5	$36.8 \pm 1.6^{\#\#\#\#}$
Outcomes, n (%)		
Gestational hypertension	0	23 (85)
Pre-eclampsia	0	6 (22)
Gestational diabetes	3 (6)	4 (15)
PPROM	3 (6)	1 (4)
Polyhydramnios	4 (9)	2 (7)
IUGR	2 (5)	0
Pre-term labor or delivery	3 (6)	0
Postpartum hemorrhage	7 (15)	4 (15)

**Table 1. Demographics, clinical characteristics, and outcomes in NT and HYP
pregnancies.** [#], P<0.05; [###], P<0.001; [####], P<0.0001 analyzed by *t*-test.

Attenuated activation of the classical RAAS over gestation in pregnancies that develop

hypertension versus remaining normotensive.

We used RAS Fingerprint with equilibrium analysis to quantify angiotensin peptides, aldosterone

concentrations, and biomarkers in serum of pregnant women in the first and third trimester of

pregnancy. Table 2 list the median and IQR for all measured and calculated components of the

RAAS in the cohort - in general, most components of the RAAS were significantly increased

over gestation in NT, but not HYP, and tended to be lower in HYP versus NT in the third

trimester.

Table 2. Serum concentrations of RAAS components in normotensive (NT) and
hypertensive (HYP) groups in the first and third trimesters of pregnancy.

RAAS Component	NT N=47	HYP N=20	P value$^@$

Ang I, pmol/L
  1st Trimester
  3rd Trimester
	
	72.7 (45.9 – 112.1)
	115.6 (69.2 – 172.7)****
		
		61.6 (36.2 – 104.1)
		71.6 (51.2 – 145.1)
			
			0.645
			0.080

Ang II, pmol/L
  1st Trimester
  3rd Trimester
	
	165.3 (110.5 – 197.0)
	180.9 (130.8 – 290.2)*
		
		143.9 (76.3 – 211.7)
		141.9 (87.8 – 244.5)
			
			0.404
			0.053

Ang III, pmol/L
  1st Trimester
  3rd Trimester
	
	4.3 (2.0 – 9.2)
	5.9 (2.0 – 10.1)
		
		2.0 (2.0 – 7.3)
		2.0 (2.0 – 4.9)
			
			0.602
			0.012

Ang IV, pmol/L
  1st Trimester
  3rd Trimester
	
	8.6 (5.3 – 12.9)
	10.1 (5.2 – 14.0)
		
		5.8 (3.4 – 10.1)
		7.4 (4.6 – 11.9)
			
			0.107
			0.149

Ang-1-5, pmol/L
  1st Trimester
  3rd Trimester
	
	5.3 (3.4 – 7.8)
	7.7 (5.3 – 10.9)**
		
		4.3 (3.0 – 8.3)
		5.2 (3.3 – 8.2)
			
			0.571
			0.084

Aldosterone, pmol/L
  1st Trimester
  3rd Trimester
	
	386.1 (226.2 – 626.2)
	970.5 (468.3 – 1586.0)****
		
		290.2 (181.3 – 791.0)
		492.5 (260.3 – 826.9)
			
			0.680
			0.003

PRA-S, pmol/L
  1st Trimester
  3rd Trimester
	
	243.2 (157.5 – 309.1)
	307.9 (214.7 – 474.8)***
		
		194.3 (126.8 – 341.7)
		223.7 (143.4 – 343.2)
			
			0.426
			0.067

ACE-S, pmol/L / pmol/L
  1st Trimester
  3rd Trimester
	
	2.16 (1.83 – 2.98)
	1.78 (1.30 – 2.08)****
		
		2.27 (1.79 – 3.21)
		1.83 (1.45 – 2.41)**
			
			0.703
			0.534

Aldosterone-Ang II ratio
(AA2-R), pmol/L / pmol/L
  1st Trimester
  3rd Trimester
	
	2.07 (1.63 – 3.33)
	4.25 (3.20 – 7.71)****
		
		2.25 (0.90 – 4.67)
		3.38 (2.04 – 6.27)
			
			0.929
			0.161

Table 2. Concentrations of angiotensin (Ang) peptides, aldosterone, and the biomarkers PRA-S, ACE-S, and AA2-R at equilibrium determined by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Data are median and interquartile range (IQR). @, NT versus HYP within trimester, analyzed by Mann-Whitney test. *, $P<0.05$, **, $P<0.01$, ***, $P<0.001$, ****, $P<0.0001$ for third trimester vs first trimester within group analyzed by Wilcoxon signed rank test. Abbreviations: PRA-S: surrogate biomarker for plasma renin activity, calculated from ([Ang I] + [Ang II]); ACE-S: surrogate biomarker for ACE activity, calculated from ([Ang II] / [Ang I]).

As previous studies of pregnancy indicated that classical biomarkers for activation of the

RAAS, PRA (or direct renin concentration) and plasma aldosterone concentrations (PAC), are

reduced in gestational hypertension or pre-eclampsia[25, 27, 52], we examined PRA-S and

aldosterone concentrations generated using RAS Fingerprint in our cohort of NT and HYP

pregnancies (Figure 1). PRA-S was significantly increased from the first to third trimester in

pregnancies that remained NT (P<0.001) with a median percent increase of 31% (Figure 1A,

1C). In contrast, PRA-S was not statistically increased in pregnancies that developed HYP

(p=0.889), and the median percent change in PRA-S over gestation in the HYP group was zero

(Figure 1A, 1C). Median values for PRA-S were not different between NT and HYP at either the

first or third trimester, although there was a trend toward a lower PRA-S in HYP versus NT in

the third trimester (p=0.067; Figure 1A, Table 2). Similarly, serum aldosterone concentrations

significantly increased over gestation in the NT group (P<0.0001), with a median percent

increase of 135%. In HYP, aldosterone rose by 57%, although the change over gestation was

not significant (p=0.141), and third trimester concentrations of aldosterone were significantly

lower in HYP versus NT (P<0.01; Figure 1B, 1D, Table 2).

Figure 1. **RAS Fingerprint-generated biomarkers for activation of the classical RAAS in**

normotensive versus hypertensive pregnancy. A) PRA-S, a surrogate for plasma activity

calculated from the sum of the equilibrium concentrations of Ang I and Ang II, and B)

aldosterone concentrations in the first and third trimesters of pregnancies that developed

hypertension after 20 weeks gestation (HYP, n=27) and those that remained normotensive (NT,

n=47). PRA-S and aldosterone levels were not different among NT and HYP in the first

trimester, but increased over gestation only in the group that remained NT. Data are median,

95th confidence intervals (CI). ***, $P<0.001$, and ****, $P<0.0001$ for within-group increase from

first to third trimester analyzed by Wilcoxon matched-pairs signed rank tests. ##, $P<0.01$

compared to NT using Mann-Whitney test. The percent change from first to third trimester in

C)PRA-S and D) aldosterone concentrations in NT and HYP patients. The percent increase

over gestation in PRA-S and aldosterone was significantly lower in pregnancies that developed

HYP compared to NT. Data are median, 95th CI of the percent change for each biomarker over

pregnancy in NT and HYP groups. #, $P<0.05$ compared to NT using Mann-Whitney test.

Metabolism of Ang II and activation of the counter-regulatory RAAS in NT and HYP

pregnancies.

We quantified angiotensin metabolites upstream (Ang I) and downstream (Ang III and Ang IV,

generated via n-terminal metabolism; and Ang-1-5 and Ang-1-7, generated via c-terminal

metabolism) from Ang II (Figure 2A-D, Table 2). In NT, Ang II concentrations were only

modestly increased across gestation ($P<0.05$), although Ang I formation was robustly increased

across pregnancy ($P<0.0001$; Figure 2A, 2B, Table 2). In the HYP group, Ang II concentrations

were not increased at all (p=0.594), but concentrations of Ang I were (non-significantly)

increased over gestation (p=0.052; Figure 2A, 2B, Table 2). There was a relative decrease in

Ang II to Ang I over gestation, reflected by a decrease in ACE-S, evident in both NT and HYP

groups (Table 2). There was a relative increase in aldosterone concentrations relative to Ang II

(AA2-R) over gestation in NT (P<0.010) but not HYP patients (p=0.141, Table 2).

Metabolism of Ang II was assessed by examining the concentrations of n- (sum of the

concentrations of Ang III and Ang IV) and c-terminal metabolites (sum of the concentrations of

Ang-1-5 and Ang-1-7), where c-terminal metabolites are reflective of activity of the counter-

regulatory arm of the RAAS[25]. Concentrations in pmol/L of n- and c-terminal metabolites of

Ang II were 10-fold lower than Ang II and Ang I concentrations in both NT and HYP groups

(Figure 2B, 2C, Table 2). Concentrations of Ang-1-7 were below the LLOQ in most patients in

the NT group (detected in only 7 and 16 patients in the first and third trimester, respectively),

and in the HYP group (detected in only 7 and 9 patients in the first and third trimester,

respectively), so median values with IQR for this analyte were less than the LLOQ and not listed

in Table 2. Half the value of the LLOQ (a concentration of 1.5 pmol/L) in those samples with

Ang-1-7 concentrations below the LLOQ was used to calculate the sum of c-terminal peptides.

The concentrations of c- and n-terminal metabolites were not different in NT versus HYP in the

first or third trimester (Figure 2C, 2D), but in the NT group, the concentration of c-terminal

metabolites significantly increased over gestation (Figure 2D).

Figure 2. Equilibrium concentrations of Ang II, and upstream and downstream angiotensin metabolites in normotensive and hypertensive pregnancy. A) Ang II and B) Ang I concentrations in the first and third trimester in NT (n=47) and HYP (n=27) groups. Data are median with 95th confidence intervals (CI). *, P<0.01, ****, P<0.01, within-group increase from first to third trimester analyzed by Wilcoxon matched-pairs signed rank tests. P=0.052 increase across gestation in HYP. C) The concentration of n-terminal metabolites of Ang II, calculated from the sum of the concentrations of Ang III and Ang IV, and D) the concentration of c-terminal metabolites of Ang II, calculated from the sum of the concentrations of Ang-1-5 and Ang-1-7. Data are median with 95th CI. P=0.053, between group analysis at the third trimester

336 analyzed via Mann-Whitney. **, P<0.01 within-group increase from first to third trimester

337 analyzed by Wilcoxon matched-pairs signed rank tests.

4. Discussion

Previous studies have demonstrated that the RAAS is suppressed in pregnancies with

pregnancy hypertension, but deviations in the activity of the RAAS compared to normotensive

pregnancy have not been comprehensively described. We used RAS Fingerprint to quantify

multiple angiotensin metabolites and biomarkers of the RAAS over gestation in pregnant women

with or without pregnancy hypertension. The main results from this study, the first to report LC-

MS/MS-based RAAS profiles in a prospective study of pregnancy hypertension, are 1) a marked

increase across gestation was evident in PRA-S, and especially aldosterone concentrations, in

NT pregnancy, but 2) not in those that developed HYP, where PRA-S was largely unchanged

after the first trimester of pregnancy, and third trimester aldosterone concentrations were

significantly lower than the NT group; 3) the increase in aldosterone secretion across gestation

was proportionally greater than the change in PRA-S or Ang II in both groups, with a more

robust effect in the NT group; and 4) c- and n-terminal metabolites, present in low

concentrations in both groups, generally increased over gestation in the NT but the HYP group.

Taken together, these findings indicate that normotensive pregnancy is associated with a

sustained increased in Ang I (and to a lesser degree, Ang II) concentrations over gestation,

accompanied by a marked elevation in aldosterone concentrations and moderate increase in

alternative RAAS metabolites. The predominate features of pregnancies that develop HYP are

stalled or waning activation of the RAAS in the second half of pregnancy (accompanied by

unchanging levels of angiotensin peptides) and attenuated secretion of aldosterone.

The comprehensive RAAS profiles generated in our study agree with previous studies

reporting low renin and aldosterone levels in normal and hypertensive pregnancy, and extend

them to include detailed activity of angiotensin peptide metabolites over gestation. PRA and

aldosterone concentrations are progressively increased with pregnancy, and can exceed non-

pregnant levels by 2-3 fold[26, 52]. PRA is increased early in gestation [53], where aldosterone

concentrations peak in the third trimester[54]. In pregnancies that develop hypertension, some

studies have shown that PRA is initially elevated as in normotensive pregnancy, but fails to

increase over gestation or decreases to non-pregnant levels[25]. Several studies have

demonstrated that, aldosterone concentrations, although reduced compared to normotensive,

still rise to some degree over pregnancy, even when PRA is declining[25, 26]. These studies are

consistent with our observations, where PRA-S and aldosterone increased over gestation only

in the NT group, but aldosterone remained elevated in in the HYP group. Our study did not

contain a non-pregnant group for comparison, but reported values of RAAS biomarkers in non-

pregnant cohorts generated with the same LC-MS/MS-based methodology are available. The

median and IQR reported for PRA-S and Ang II in a cohort of 77 individuals with hypertension

was 165.6 (80.6–328.3) pmol/L and 100.9 (56.3–227.0) pmol/L, respectively[32]. These values

are substantially lower than PRA-S and Ang II values reported here in the third trimester of the

HYP group, suggesting that RAAS activity was still higher compared to non-pregnant state.

Because pre-eclampsia is associated with lower plasma volume [54], suppression of the

RAAS is somewhat paradoxical. In longitudinal studies of pregnancies that developed

gestational hypertension or pre-eclampsia, downward trending of PRA levels over pregnancy

correlated with the onset of high blood pressure [25, 26, 55]. In our study, patients that

developed HYP failed to increase RAS components over pregnancy, and had generally lower

concentrations of angiotensin peptides in the third trimester. Downregulation of renin activity

with disease course suggests a compensatory response to high blood pressure[55], rather than

a primary event in the pathogenesis of the disease. An additional explanation for low activation

of the RAAS in hypertensive pregnancies could be reduced concentration or availability of

AGT[56], the substrate for renin. Langer et al previously made the observation that first trimester

Ang I levels were low compared to Ang II (similar to our study), and suggested that Ang II

synthesis was not limited by renin, but rather perhaps by AGT [52].

Historical studies by Gant et al demonstrate that normotensive pregnancies become

refractory to the pressor effects of Ang II, presumably for protection against vasoconstrictive

effects of Ang II, where pregnancies that develop hypertension progressively lose this response

over the second half of pregnancy [57]. This suggests factors impacting AT_1 receptor signaling

in pregnancy, such as presence or absence of AT_2 receptors[58], metabolic

derangements{34658252}, or AT_1 autoantibody-binding might facilitate negative cellular effects

of Ang II (promotion of inflammation[59] or renal[60]), that lead to the progression of

hypertension. In our cohort, blood pressure was elevated in HYP compared to NT in the first

trimester, suggesting the presence of underlying vascular dysfunction in this group, potentially

caused by previous pre-eclampsia or type 1 diabetes exhibited in this group.

Factors contributing to aldosterone secretion in hypertensive pregnancy are complex.

Previous studies reported that aldosterone concentrations in pregnancy exceeded those

expected on the basis of renin levels[57]. In our study, aldosterone concentrations relative to

Ang II were significantly increased over gestation only in NT groups, but HYP pregnancies still

had elevated aldosterone compared to non-pregnant cohorts[32] in the second half of

pregnancy, despite no sustained activation of the RAAS. These data suggest non-Ang II

stimulation of aldosterone is a feature of both normotensive and hypertensive pregnancy, but

the possibility of altered sensitivity of AT_1 receptors to Ang II in the adrenal cortex in one group

compared to another is not excluded. Purported non-angiotensin stimulants of aldosterone in

pregnancy include ACTH, where ACTH simulated aldosterone not only in normotensive but also

hypertensive pregnancies[61], and VEGF [62]. In pre-eclampsia, the presence of circulating

factors such as the VEGF receptor binding splice variant, sFlts-1, and AT_1-autoantibodies, may

impair aldosterone synthesis or release[63]. In addition, aldosterone concentrations could be

suppressed by excess sodium in pre-eclampsia resulting from activation of epithelial sodium

channels (ENaC)[64]. Notably, gain of function variants in aldosterone synthase (CYP11B2)

were preferably present in normotensive versus pre-eclamptic pregnancies, suggesting an

evolutionary basis for an active mineralocorticoid receptor system to protect against pre-

eclampsia[65].

Enhanced concentrations of Ang-1-7 were reported in normal pregnancy, and reduced

concentrations in pre-eclampsia, where authors hypothesized that Ang-1-7 may function in

healthy pregnancy to oppose potentially adverse (vasoconstrictive) effects of Ang II[29, 66].

Similarly, in a recent study, plasma Ang-(1-7) concentrations were elevated throughout

pregnancy compared to a non-pregnant control group, and reduced in preeclampsia[28],

suggesting a protective effect of ACE2 against hypertension during pregnancy via generation of

Ang-1-7. In contrast, we report limited detection of Ang-1-7 in NT and HYP patients (using mass

spectrometry, which is the gold standard for quantification of biological molecules and a major

strength of our study[67, 68]); in samples where Ang-1-7 was detected, concentrations were

significantly lower than those reported in other studies via radioimmunoassay[28, 29].

Discrepancies in reported values likely result from different methodologies used for the

detection of Ang-1-7, where cross-reactivity in antibody-based assays, (as peptide sequences

may only differ by one or two amino acids), may explain artificially high measured

concentrations of Ang-1-7[69]. Notably, reliability of ELISA for quantification of angiotensin-(1-7)

has recently been called into question[70]). Ang-1-5, a c-terminal metabolite of Ang-1-7, is

considered a component of the alternative RAAS[51, 71]. Ang-1-5 was readily detected in our

study by mass spectrometry, so we used the sum of Ang-1-7 and Ang-1-6 concentrations as an

indicator of the alternative RAAS. Concentration of Ang-1-7 + Ang-1-5 did increase over

gestation in NT, but not HYP pregnancies. However, concentrations of angiotensin metabolites

downstream from Ang II, (whether c- or n-terminally degraded), 10-fold less than the

concentrations of Ang II and Ang I. This data suggests the main bioactive effector of the RAAS

is Ang II, and that modulatory effects of Ang-1-7 in pregnancy are likely specific to local

tissues[72].

Our study has several limitations. We did not differentiate among pre-eclampsia and

gestational hypertension due to small numbers. Pre-eclampsia, especially, is a heterogenous

disease, where some subtypes may result from a different pathophysiology[6], with a different

RAAS profile. Also, our study did not control for sodium or volume status, which could affect

concentrations of aldosterone and PRA-S. Although previous studies have indicated that

sensitivity of renin and aldosterone to salt are blunted in pregnancy[57, 73], differences in salt

and aldosterone relationships in pregnancy hypertension versus normotensive are not well-

understood.

5. Conclusions

In summary, we sought to define prominent features of RAAS activity associated with the

development of pregnancy hypertension using a novel methodology for comprehensive

assessment of the RAAS. Concentrations of PRA-S, angiotensin peptides, and aldosterone

were not different among NT and HYP in the first trimester, significantly increased over

gestation only in the group that remained NT, and tended to be lower in the third trimester in

HYP compared to NT. We conclude that pregnancies that develop HYP are characterized by

stalled or waning activation of the RAAS in the second half of pregnancy (accompanied by

unchanging levels of angiotensin peptides) and attenuated secretion of aldosterone. Clinical

application of this knowledge may inform detection or treatment of pregnancy hypertension or

related adverse outcomes.

Author contributions. Study conception and design (JAB, JOB, AS); clinical data collection

(KV, AS, HH, CC); blood analysis of RAS and interpretation (RS, MP); analysis and

interpretation of results (RS, MP, AS, JAB, JOB); manuscript preparation (RS).

Sources of funding. The work was supported in part by a grant from the Kentucky BIRCWH

Program, NIDA 5K12DA035150 (RS) and by the Kentucky Children's Hospital Children's

Miracle Network Research Fund.

Institutional Review Board Statement: The study was conducted in accordance with the

Declaration of Helsinki, and approved by the Institutional Review Board at the University of

Kentucky. All study procedures/methods were performed in accordance with relevant guidelines

and regulations.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the

study.

Data availability. Data may be made available by investigators upon reasonable request to

corresponding author: robin.shoemaker@uky.edu.

Competing interests. M. Poglitsch is an employee at Attoquant Diagnostics, a company

developing angiotensin-based biomarkers for hypertension. The other authors report no

conflicts.

6. References

1.   Wen, T.; Schmidt, C. N.; Sobhani, N. C.; Guglielminotti, J.; Miller, E. C.; Sutton, D.; Lahtermaher,
Y.; D'Alton, M. E.; Friedman, A. M., Trends and outcomes for deliveries with hypertensive
disorders of pregnancy from 2000 to 2018: A repeated cross-sectional study. *BJOG* **2022,** 129,
(7), 1050-1060.
2.   Alexander, B. T.; South, A. M.; August, P.; Bertagnolli, M.; Ferranti, E. P.; Grobe, J. L.; Jones, E. J.;
Loria, A. S.; Safdar, B.; Sequeira-Lopez, M. L. S.; American Heart Association Council on the
Kidney in Cardiovascular, D.; Council on, C.; Stroke, N.; Council on Cardiovascular, R.;
Intervention; Council on, H.; Council on, L.; Cardiometabolic, H., Appraising the Preclinical
Evidence of the Role of the Renin-Angiotensin-Aldosterone System in Antenatal Programming of
Maternal and Offspring Cardiovascular Health Across the Life Course: Moving the Field Forward:
A Scientific Statement From the American Heart Association. *Hypertension* **2023,** 80, (5), e75-
e89.

3.   Cirillo, P. M.; Cohn, B. A., Pregnancy complications and cardiovascular disease death: 50-year
follow-up of the Child Health and Development Studies pregnancy cohort. *Circulation* **2015,** 132,
(13), 1234-42.
4.   Lo, C. C. W.; Lo, A. C. Q.; Leow, S. H.; Fisher, G.; Corker, B.; Batho, O.; Morris, B.; Chowaniec, M.;
Vladutiu, C. J.; Fraser, A.; Oliver-Williams, C., Future Cardiovascular Disease Risk for Women
With Gestational Hypertension: A Systematic Review and Meta-Analysis. *J Am Heart Assoc* **2020,**
9, (13), e013991.
5.   Rana, S.; Lemoine, E.; Granger, J. P.; Karumanchi, S. A., Preeclampsia: Pathophysiology,
Challenges, and Perspectives. *Circ Res* **2019,** 124, (7), 1094-1112.
6.   Society for Maternal-Fetal Medicine . Electronic address, p. s. o., Executive summary: Workshop
on Preeclampsia, January 25-26, 2021, cosponsored by the Society for Maternal-Fetal Medicine
and the Preeclampsia Foundation. *Am J Obstet Gynecol* **2021,** 225, (3), B2-B7.
7.   Wu, C. H.; Mohammadmoradi, S.; Chen, J. Z.; Sawada, H.; Daugherty, A.; Lu, H. S., Renin-
Angiotensin System and Cardiovascular Functions. *Arterioscler Thromb Vasc Biol* **2018,** 38, (7),
e108-e116.
8.   Irani, R. A.; Xia, Y., The functional role of the renin-angiotensin system in pregnancy and
preeclampsia. *Placenta* **2008,** 29, (9), 763-71.
9.   Johns, D. W.; Peach, M. J.; Gomez, R. A.; Inagami, T.; Carey, R. M., Angiotensin II regulates renin
gene expression. *Am J Physiol* **1990,** 259, (6 Pt 2), F882-7.
10.   Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.;
Hsieh, F.; Acton, S.; Patane, M.; Nichols, A.; Tummino, P., Hydrolysis of biological peptides by
human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem* **2002,** 277, (17),
14838-43.
11.   Ferrario, C. M.; Chappell, M. C.; Tallant, E. A.; Brosnihan, K. B.; Diz, D. I., Counterregulatory
actions of angiotensin-(1-7). *Hypertension* **1997,** 30, (3 Pt 2), 535-41.
12.   Allen, A. M.; Zhuo, J.; Mendelsohn, F. A., Localization and function of angiotensin AT1 receptors.
Am J Hypertens **2000,** 13, (1 Pt 2), 31S-38S.
13.   Forrester, S. J.; Booz, G. W.; Sigmund, C. D.; Coffman, T. M.; Kawai, T.; Rizzo, V.; Scalia, R.;
Eguchi, S., Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and
Pathophysiology. *Physiol Rev* **2018,** 98, (3), 1627-1738.
14.   Montezano, A. C.; Nguyen Dinh Cat, A.; Rios, F. J.; Touyz, R. M., Angiotensin II and vascular
injury. *Curr Hypertens Rep* **2014,** 16, (6), 431.
15.   Minas, J. N.; Thorwald, M. A.; Conte, D.; Vazquez-Medina, J. P.; Nishiyama, A.; Ortiz, R. M.,
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in
angiotensin II-infused rats. *Clin Exp Pharmacol Physiol* **2015,** 42, (11), 1178-88.
16.   Binder, C.; Poglitsch, M.; Agibetov, A.; Duca, F.; Zotter-Tufaro, C.; Nitsche, C.; Aschauer, S.;
Kammerlander, A. A.; Oeztuerk, B.; Hengstenberg, C.; Mascherbauer, J.; Bonderman, D., Angs
(Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With
Heart Failure and Preserved Ejection Fraction. *Hypertension* **2019,** 74, (2), 285-294.
17.   Ramchand, J.; Patel, S. K.; Kearney, L. G.; Matalanis, G.; Farouque, O.; Srivastava, P. M.; Burrell,
L. M., Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated With Severe
Myocardial Fibrosis. *JACC Cardiovasc Imaging* **2020,** 13, (3), 655-664.
18.   Wong, D. W.; Oudit, G. Y.; Reich, H.; Kassiri, Z.; Zhou, J.; Liu, Q. C.; Backx, P. H.; Penninger, J. M.;
Herzenberg, A. M.; Scholey, J. W., Loss of angiotensin-converting enzyme-2 (Ace2) accelerates
diabetic kidney injury. *Am J Pathol* **2007,** 171, (2), 438-51.
19.   Patel, S. K.; Juno, J. A.; Lee, W. S.; Wragg, K. M.; Hogarth, P. M.; Kent, S. J.; Burrell, L. M., Plasma
ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19
pathogenesis and consequences. *Eur Respir J* **2021,** 57, (5).

20. Weinberger, M. H.; Kramer, N. J.; Petersen, L. P.; Cleary, R. E.; Young, P. C., Sequential changes
in the renin--angiotensin--aldosterone systems and plasma progesterone concentration in
normal and abnormal human pregnancy. *Perspect Nephrol Hypertens* **1976,** 5, 263-9.
21. Brown, M. A.; Zammit, V. C.; Mitar, D. A.; Whitworth, J. A., Renin-aldosterone relationships in
pregnancy-induced hypertension. *Am J Hypertens* **1992,** 5, (6 Pt 1), 366-71.
22. Bentley-Lewis, R.; Graves, S. W.; Seely, E. W., The renin-aldosterone response to stimulation and
suppression during normal pregnancy. *Hypertens Pregnancy* **2005,** 24, (1), 1-16.
23. Verdonk, K.; Visser, W.; Van Den Meiracker, A. H.; Danser, A. H., The renin-angiotensin-
aldosterone system in pre-eclampsia: the delicate balance between good and bad. *Clin Sci*
(Lond) **2014,** 126, (8), 537-44.
24. Jensen, E.; Wood, C.; Keller-Wood, M., The normal increase in adrenal secretion during
pregnancy contributes to maternal volume expansion and fetal homeostasis. *J Soc Gynecol*
Investig **2002,** 9, (6), 362-71.
25. Tsai, Y. L.; Wu, S. J.; Chen, Y. M.; Hsieh, B. S., Changes in renin activity, aldosterone level and
electrolytes in pregnancy-induced hypertension. *J Formos Med Assoc* **1993,** 92, (6), 514-8.
26. Elsheikh, A.; Creatsas, G.; Mastorakos, G.; Milingos, S.; Loutradis, D.; Michalas, S., The renin-
aldosterone system during normal and hypertensive pregnancy. *Arch Gynecol Obstet* **2001,** 264,
(4), 182-5.
27. Zitouni, H.; Raguema, N.; Gannoun, M. B. A.; Hebert-Stutter, M.; Zouari, I.; Maleh, W.; Faleh, R.;
Letaifa, D. B.; Almawi, W. Y.; Fournier, T.; Mahjoub, T.; Guibourdenche, J., Impact of obesity on
the association of active renin and plasma aldosterone concentrations, and aldosterone-to-renin
ratio with preeclampsia. *Pregnancy Hypertens* **2018,** 14, 139-144.
28. Tamanna, S.; Clifton, V. L.; Rae, K.; van Helden, D. F.; Lumbers, E. R.; Pringle, K. G., Angiotensin
Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age. *Front*
Physiol **2020,** 11, 590787.
29. Merrill, D. C.; Karoly, M.; Chen, K.; Ferrario, C. M.; Brosnihan, K. B., Angiotensin-(1-7) in normal
and preeclamptic pregnancy. *Endocrine* **2002,** 18, (3), 239-45.
30. Sykes, S. D.; Pringle, K. G.; Zhou, A.; Dekker, G. A.; Roberts, C. T.; Lumbers, E. R.; consortium, S.,
Fetal sex and the circulating renin-angiotensin system during early gestation in women who
later develop preeclampsia or gestational hypertension. *J Hum Hypertens* **2014,** 28, (2), 133-9.
31. J, J. S.; M, A. B., Renin-angiotensin system in pre-eclampsia: everything old is new again. *Obstet*
Med **2012,** 5, (4), 147-153.
32. Burrello, J.; Buffolo, F.; Domenig, O.; Tetti, M.; Pecori, A.; Monticone, S.; Poglitsch, M.; Mulatero,
P., Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary
Aldosteronism. *Hypertension* **2020,** 75, (1), 163-172.
33. Binder, C.; Poglitsch, M.; Duca, F.; Rettl, R.; Dachs, T. M.; Dalos, D.; Schrutka, L.; Seirer, B.; Ligios,
L. C.; Capelle, C.; Eslam, R. B.; Qin, H.; Hengstenberg, C.; Bonderman, D., Renin Feedback Is an
Independent Predictor of Outcome in HFpEF. *J Pers Med* **2021,** 11, (5).
34. Pavo, N.; Goliasch, G.; Wurm, R.; Novak, J.; Strunk, G.; Gyongyosi, M.; Poglitsch, M.; Saemann,
M. D.; Hulsmann, M., Low- and High-renin Heart Failure Phenotypes with Clinical Implications.
Clin Chem **2018,** 64, (3), 597-608.
35. Jha, S.; Taschler, U.; Domenig, O.; Poglitsch, M.; Bourgeois, B.; Pollheimer, M.; Pusch, L. M.;
Malovan, G.; Frank, S.; Madl, T.; Gruber, K.; Zimmermann, R.; Macheroux, P., Dipeptidyl
peptidase 3 modulates the renin-angiotensin system in mice. *J Biol Chem* **2020,** 295, (40), 13711-
13723.
36. Wolf, P.; Mayr, J.; Beiglbock, H.; Fellinger, P.; Winhofer, Y.; Poglitsch, M.; Gessl, A.; Kautzky-
Willer, A.; Luger, A.; Krebs, M., Identifying a disease-specific renin-angiotensin-aldosterone

system fingerprint in patients with primary adrenal insufficiency. *Eur J Endocrinol* **2019,** 181, (1),
39-44.

37. LeFevre, M. L.; Force, U. S. P. S. T., Low-dose aspirin use for the prevention of morbidity and
mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement.
Ann Intern Med **2014,** 161, (11), 819-26.

38. Pickering, T. G.; Hall, J. E.; Appel, L. J.; Falkner, B. E.; Graves, J. W.; Hill, M. N.; Jones, D. H.; Kurtz,
T.; Sheps, S. G.; Roccella, E. J.; Council on High Blood Pressure Research, P.; Public Education
Subcommittee, A. H. A., Recommendations for blood pressure measurement in humans: an AHA
scientific statement from the Council on High Blood Pressure Research Professional and Public
Education Subcommittee. *J Clin Hypertens (Greenwich)* **2005,** 7, (2), 102-9.

39. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists'
Task Force on Hypertension in Pregnancy. *Obstet Gynecol* **2013,** 122, (5), 1122-1131.

40. Haschke, M.; Schuster, M.; Poglitsch, M.; Loibner, H.; Salzberg, M.; Bruggisser, M.; Penninger, J.;
Krähenbühl, S., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-
converting enzyme 2 in healthy human subjects. *Clin Pharmacokinet* **2013,** 52, (9), 783-92.

41. Guo, Z.; Poglitsch, M.; McWhinney, B. C.; Ungerer, J. P. J.; Ahmed, A. H.; Gordon, R. D.; Wolley,
M.; Stowasser, M., Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary
Aldosteronism. *Clin Chem* **2020,** 66, (3), 483-492.

42. Bernstone, L.; Adaway, J. E.; Keevil, B. G., An LC-MS/MS assay for analysis of equilibrium
angiotensin II in human serum. *Ann Clin Biochem* **2021,** 45632211008923.

43. Basu, R.; Poglitsch, M.; Yogasundaram, H.; Thomas, J.; Rowe, B. H.; Oudit, G. Y., Roles of
Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. *J Am Coll Cardiol* **2017,** 69,
(7), 805-819.

44. van Rooyen, J. M.; Poglitsch, M.; Huisman, H. W.; Mels, C.; Kruger, R.; Malan, L.; Botha, S.;
Lammertyn, L.; Gafane, L.; Schutte, A. E., Quantification of systemic renin-angiotensin system
peptides of hypertensive black and white African men established from the RAS-Fingerprint(R). *J*
Renin Angiotensin Aldosterone Syst **2016,** 17, (4).

45. van Rooyen, J. M.; Poglitsch, M.; Huisman, H. W.; Gafane-Matemane, L. F.; Breet, Y.; Malan, L., A
primary aldosteronism-like phenotype identified with the aldosterone-to-angiotensin II ratio in
black men: the SABPA study. *Cardiovasc J Afr* **2020,** 31, (3), 130-135.

46. Gafane-Matemane, L. F.; Mokae, N. L.; Breet, Y.; Poglitsch, M.; Schutte, A. E., Associations of
central and peripheral blood pressure with the renin-angiotensin-aldosterone system in healthy
young adults: the African-PREDICT study. *Hypertens Res* **2021,** 44, (4), 435-445.

47. Wang, K.; Basu, R.; Poglitsch, M.; Bakal, J. A.; Oudit, G. Y., Elevated Angiotensin 1-7/Angiotensin
II Ratio Predicts Favorable Outcomes in Patients With Heart Failure. *Circ Heart Fail* **2020,** 13, (7),
e006939.

48. Reindl-Schwaighofer, R.; Hödlmoser, S.; Eskandary, F.; Poglitsch, M.; Bonderman, D.; Strassl, R.;
Aberle, J. H.; Oberbauer, R.; Zoufaly, A.; Hecking, M., Angiotensin-Converting Enzyme 2 (ACE2)
Elevation in Severe COVID-19. *Am J Respir Crit Care Med* **2021**.

49. Krenn, K.; Hobart, P.; Poglitsch, M.; Croize, A.; Ullrich, R., Equilibrium Angiotensin Metabolite
Profiling in Patients with Acute Respiratory Distress Syndrome Indicates Angiotensin-Converting
Enzyme Inhibition. *Am J Respir Crit Care Med* **2020,** 202, (10), 1468-1471.

50. Antlanger, M.; Bernhofer, S.; Kovarik, J. J.; Kopecky, C.; Kaltenecker, C. C.; Domenig, O.;
Poglitsch, M.; Saemann, M. D., Effects of direct renin inhibition versus angiotensin II receptor
blockade on angiotensin profiles in non-diabetic chronic kidney disease. *Ann Med* **2017,** 49, (6),
525-533.

51. Hartl, L.; Rumpf, B.; Domenig, O.; Simbrunner, B.; Paternostro, R.; Jachs, M.; Poglitsch, M.;
Marculescu, R.; Trauner, M.; Reindl-Schwaighofer, R.; Hecking, M.; Mandorfer, M.; Reiberger, T.,

The systemic and hepatic alternative renin-angiotensin system is activated in liver cirrhosis,
linked to endothelial dysfunction and inflammation. *Sci Rep* **2023,** 13, (1), 953.

52. Langer, B.; Grima, M.; Coquard, C.; Bader, A. M.; Schlaeder, G.; Imbs, J. L., Plasma active renin,
angiotensin I, and angiotensin II during pregnancy and in preeclampsia. *Obstet Gynecol* **1998,** 91,
(2), 196-202.

53. Wiegel, R. E.; Jan Danser, A. H.; Steegers-Theunissen, R. P. M.; Laven, J. S. E.; Willemsen, S. P.;
Baker, V. L.; Steegers, E. A. P.; von Versen-Hoynck, F., Determinants of Maternal Renin-
Angiotensin-Aldosterone-System Activation in Early Pregnancy: Insights From 2 Cohorts. *J Clin*
Endocrinol Metab **2020,** 105, (11).

54. Salas, S. P.; Marshall, G.; Gutierrez, B. L.; Rosso, P., Time course of maternal plasma volume and
hormonal changes in women with preeclampsia or fetal growth restriction. *Hypertension* **2006,**
47, (2), 203-8.

55. Malha, L.; Sison, C. P.; Helseth, G.; Sealey, J. E.; August, P., Renin-Angiotensin-Aldosterone
Profiles in Pregnant Women With Chronic Hypertension. *Hypertension* **2018,** 72, (2), 417-424.

56. Satou, R.; Kobori, H.; Katsurada, A.; Miyata, K.; Navar, L. G., Quantification of intact plasma AGT
consisting of oxidized and reduced conformations using a modified ELISA. *Am J Physiol Renal*
Physiol **2016,** 311, (6), F1211-F1216.

57. Brown, M. A.; Nicholson, E.; Gallery, E. D., Sodium-renin-aldosterone relations in normal and
hypertensive pregnancy. *Br J Obstet Gynaecol* **1988,** 95, (12), 1237-46.

58. Mishra, J. S.; Gopalakrishnan, K.; Kumar, S., Pregnancy upregulates angiotensin type 2 receptor
expression and increases blood flow in uterine arteries of rats. *Biol Reprod* **2018,** 99, (5), 1091-
1099.

59. Satou, R.; Penrose, H.; Navar, L. G., Inflammation as a Regulator of the Renin-Angiotensin
System and Blood Pressure. *Curr Hypertens Rep* **2018,** 20, (12), 100.

60. Li, X. C.; Leite, A. P. O.; Zheng, X.; Zhao, C.; Chen, X.; Zhang, L.; Zhou, X.; Rubera, I.; Tauc, M.;
Zhuo, J. L., Proximal Tubule-Specific Deletion of Angiotensin II Type 1a Receptors in the Kidney
Attenuates Circulating and Intratubular Angiotensin II-Induced Hypertension in PT-Agtr1a(-/-)
Mice. *Hypertension* **2021,** 77, (4), 1285-1298.

61. Brown, M. A.; Thou, S. T.; Whitworth, J. A., Stimulation of aldosterone by ACTH in normal and
hypertensive pregnancy. *Am J Hypertens* **1995,** 8, (3), 260-7.

62. Gennari-Moser, C.; Khankin, E. V.; Escher, G.; Burkhard, F.; Frey, B. M.; Karumanchi, S. A.; Frey,
F. J.; Mohaupt, M. G., Vascular endothelial growth factor-A and aldosterone: relevance to
normal pregnancy and preeclampsia. *Hypertension* **2013,** 61, (5), 1111-7.

63. Siddiqui, A. H.; Irani, R. A.; Zhang, W.; Wang, W.; Blackwell, S. C.; Kellems, R. E.; Xia, Y.,
Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1
induction contributes to impaired adrenal vasculature and decreased aldosterone production in
preeclampsia. *Hypertension* **2013,** 61, (2), 472-9.

64. Marino, G. I.; Kotsias, B. A., Expression of the epithelial sodium channel sensitive to amiloride
(ENaC) in normal and preeclamptic human placenta. *Placenta* **2013,** 34, (2), 197-200.

65. Escher, G.; Cristiano, M.; Causevic, M.; Baumann, M.; Frey, F. J.; Surbek, D.; Mohaupt, M. G.,
High aldosterone-to-renin variants of CYP11B2 and pregnancy outcome. *Nephrol Dial Transplant*
2009, 24, (6), 1870-5.

66. Brosnihan, K. B.; Neves, L. A.; Anton, L.; Joyner, J.; Valdes, G.; Merrill, D. C., Enhanced expression
of Ang-(1-7) during pregnancy. *Braz J Med Biol Res* **2004,** 37, (8), 1255-62.

67. Rehan, M.; Raizman, J. E.; Cavalier, E.; Don-Wauchope, A. C.; Holmes, D. T., Laboratory
challenges in primary aldosteronism screening and diagnosis. *Clin Biochem* **2015,** 48, (6), 377-87.

68. Webster, L. M.; Gill, C.; Seed, P. T.; Bramham, K.; Wiesender, C.; Nelson-Piercy, C.; Myers, J. E.;
Chappell, L. C., Chronic hypertension in pregnancy: impact of ethnicity and superimposed

preeclampsia on placental, endothelial, and renal biomarkers. *Am J Physiol Regul Integr Comp*
Physiol **2018,** 315, (1), R36-R47.
69. Chappell, M. C., Biochemical evaluation of the renin-angiotensin system: the good, bad, and
absolute? *Am J Physiol Heart Circ Physiol* **2016,** 310, (2), H137-52.
70. Chappell, M. C.; Pirro, N. T.; South, A. M.; Gwathmey, T. M., Concerns on the Specificity of
Commercial ELISAs for the Measurement of Angiotensin (1-7) and Angiotensin II in Human
Plasma. *Hypertension* **2021,** 77, (3), e29-e31.
71. Park, B. M.; Li, W.; Kim, S. H., Cardio-protective effects of angiotensin-(1-5) via mas receptor in
rats against ischemic-perfusion injury. *Peptides* **2021,** 139, 170516.
72. Delforce, S. J.; Lumbers, E. R.; Ellery, S. J.; Murthi, P.; Pringle, K. G., Dysregulation of the
placental renin-angiotensin system in human fetal growth restriction. *Reproduction* **2019,** 158,
(3), 237-245.
73. Gennari-Moser, C.; Escher, G.; Kramer, S.; Dick, B.; Eisele, N.; Baumann, M.; Raio, L.; Frey, F. J.;
Surbek, D.; Mohaupt, M. G., Normotensive blood pressure in pregnancy: the role of salt and
aldosterone. *Hypertension* **2014,** 63, (2), 362-8.

697